Journal of perinatology : official journal of the California Perinatal Association · 2026
Therapeutic hypothermia and in-hospital mortality in 35-week infants with encephalopathy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Aly Hany, Eltaly Hatem, Mohamed Farah A, Saker Firas, Acun Ceyda, Mohamed Mohamed A
Аннотация
OBJECTIVES: Therapeutic hypothermia (TH) improves outcomes in infants ≥36 weeks with HIE, although safety at 35weeks remains uncertain. We compared TH utilization and associated outcomes in 35- versus 36-week infants with HIE.
STUDY DESIGN: Using the 2016-2022 National Inpatient Sample, we identified 35- and 36-week infants with HIE. The primary outcome was in-hospital mortality; secondary outcomes included coagulopathy and other complications. Logistic regression adjusted for covariates; Cochran-Armitage tested trends in TH use.
RESULTS: Among 1,397,680 infants, HIE occurred in 2354 (0.48%) at 35 weeks and 3972 (0.44%) at 36 weeks; in-hospital mortality was similar (9.98% vs 9.99%). TH was less frequently used at 35 weeks (19.8% vs 22.4%) but increased over time (p < 0.001). 35-week treated infants had higher unadjusted in-hospital mortality (10.3% vs 6.8%) and coagulopathy (28.7% vs 18.4%); adjusted in-hospital mortality did not differ.
CONCLUSION: TH use at 35 weeks is increasing that was not associated with differences in in-hospital mortality. Prospective studies are needed to define its role.
STUDY DESIGN: Using the 2016-2022 National Inpatient Sample, we identified 35- and 36-week infants with HIE. The primary outcome was in-hospital mortality; secondary outcomes included coagulopathy and other complications. Logistic regression adjusted for covariates; Cochran-Armitage tested trends in TH use.
RESULTS: Among 1,397,680 infants, HIE occurred in 2354 (0.48%) at 35 weeks and 3972 (0.44%) at 36 weeks; in-hospital mortality was similar (9.98% vs 9.99%). TH was less frequently used at 35 weeks (19.8% vs 22.4%) but increased over time (p < 0.001). 35-week treated infants had higher unadjusted in-hospital mortality (10.3% vs 6.8%) and coagulopathy (28.7% vs 18.4%); adjusted in-hospital mortality did not differ.
CONCLUSION: TH use at 35 weeks is increasing that was not associated with differences in in-hospital mortality. Prospective studies are needed to define its role.